Janus Henderson Group PLC Magenta Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.26 - $2.09 $384,456 - $637,709	305,124 Added 10.16%	3,308,899 $4.75 Million
Q2 2022 Aug 15, 2022	BUY	$0.97 - $3.08 $1.06 Million - $3.35 Million	1,089,049 Added 56.88%	3,003,775 $3.57 Million
Q1 2022 May 16, 2022	BUY	$2.55 - $5.23 $4.5 Million - $9.22 Million	1,762,776 Added 1160.1%	1,914,726 $5.53 Million
Q4 2021 Feb 14, 2022	SELL	$4.43 - $8.33 $1.97 Million - $3.7 Million	-444,452 Reduced 74.52%	151,950 $672,000
Q3 2021 Nov 16, 2021	BUY	$6.07 - $9.89 $2.92 Million - $4.76 Million	481,753 Added 420.2%	596,402 $4.34 Million
Q2 2021 Aug 16, 2021	SELL	$9.76 - $14.15 $1.05 Million - $1.53 Million	-107,856 Reduced 48.47%	114,649 $1.12 Million
Q1 2021 May 17, 2021	BUY	$7.66 - $13.38 $1.7 Million - $2.98 Million	222,505 New	222,505 $2.63 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.